BASKING RIDGE, NEW JERSEY, January 6, 2016 (Newswire.com) - ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016.
Desitin, who are a pan European pharma based in Hamburg, presently focus on treatments in Parkinson’s and epilepsy. Their existing CNS salesforces covering these diseases will also detail gammaCore to those specialist neurologists who also treat headache.
GammaCore is well known in Germany as many of the headache centres across the country took part in the successful clinical trial program.
CEO of electroCore JP Errico commented, “We are very pleased to partner with Desitin. Their understanding of the CNS marketplace in Germany will bring great benefits to patients. It was very important to us to have a pharmaceutical partner as they better understand the business model which is most appropriate for bioelectronics.”
CEO of Desitin commented, “We believe that with our expertise in the CNS area and with a specialist salesforce we will be able to explain the significant therapeutic benefits of gammaCore firstly to the neurologists and through them to the patients. Compared to most treatments in this area gammaCore has virtually no side effects and has proven to be very effective in both preventing and treating cluster headache and migraine. We are really delighted to be working with electroCore to bring this treatment to patients across Germany.”
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.
DESITIN ARZNEIMITTEL GMBH which was founded in 1919 and is based in Hamburg is a medium sized pharma focused on the development and sales of medication for illnesses of the central nervous system (CNS) particularly the treatment of epilepsy, Morbus Parkinson, dystonia and now primary headache.
The company activities are focused on Europe with subsidiaries in 11 countries and distributors in 12 others.